

March 1, 2019

To	To
Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051	The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sirs,

Sub: Clarification on news item appeared in Business Standard on February 27, 2019 titled "Lacunae in Aurobindo Pharma's Medak facility in Andhra, says FDA report" and in Financial Express on February 28, 2019 titled "Lacunae in Aurobindo Pharma's facility: FDA report"

Ref : Email received on February 28, 2019 from NSE and BSE

This has reference to your above cited e-mails seeking clarification on the subject matter.

In this regard, we inform you that the United States Food and Drug Administration (US FDA / Regulator) had conducted an inspection at our Company's Unit IV, a formulation manufacturing facility located at Pashamylaram, Hyderabad from 3rd December 2018 to 14th December 2018. In this regard, the Company has received a "Form 483" with two observations. None of the observations are related to data integrity or repeated observations and the observations are more procedural in nature.

The Company has responded to US FDA within the stipulated time and we are also engaging with the Regulator in this process.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED


B. Adi Reddy
Company Secretary



(CIN : L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No. 11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. off.: Plot No. 2, Maithriviham, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com